Livio Di Matteo (Ph.D., M.A., B.A.)

Livio Di Matteo is Professor of Economics at Lakehead University in Thunder Bay, Ontario and specializes in  health economics, public policy, and economic history. His health economics work examines health-care spending and its sustainability.  He co-edited Bending the Cost Curve in Health Care: Canada's Provinces in International Perspective (University of Toronto Press: 2014) and recently published work in Canadian Public Policy, The European Review of Economic History, The International Journal of Health Economics and Management, Health Policy and the Canadian Journal of Economics. Di Matteo is a member of the CIHI National Health Expenditure Advisory Panel, the Evidence Network, the Research Advisory Board of the Northern Policy Institute, Senior Fellow with the Fraser Institute and a contributor to the economics blog, Worthwhile Canadian Initiative. He has been listed in Canadian Who’s Who since 1995 and holds a Ph.D. from McMaster University, an M.A. from the University of Western Ontario, and a B.A. from Lakehead University.

Brian Ferguson (Ph.D., M.A., B.A.)

Brian Ferguson is a retired professor of economics at the University of Guelph, where he taught health economics and history of economic thought.  Dr. Ferguson is the co-author of two books on the modelling of dynamic economic processes and articles on health economics with a focus on the economic modelling of addictive substances.  His past research includes work on the economic implications of population ageing.  He has written several papers on health policy and economics for the Atlantic Institute for Market Studies and has worked at the Kansas Health Institute and Health Canada, and is a member of the editorial board of the journal Substance Use and Misuse. His research includes the modelling of pharmaceutical pricing decisions in a long run dynamic framework.  He has also worked, in conjunction with Prof. Audrey Laporte of the University of Toronto, on a series of lectures on health economics.

Mary G Griffith (J.D., M.B.A., B.A.)

Mary Griffith is a member of both the New York and Ontario Bars. Her practice focuses on business law matters, particularly regulatory, advertising and marketing issues, and on developing preventive and practical approaches to business situations. She is a consultant to Advertising Standards Canada and has spoken at many conferences on a variety of legal issues. Prior to obtaining her law degree, Ms. Griffith had an extensive business career, holding a number of senior marketing executive positions with major multi-national corporations. She has also provided strategic business counsel to a team of legal and commercial consultants in the assessment and creation of joint ventures and investments both domestically and internationally. She holds a B.A. from Queen's University, an M.B.A. from the University of Toronto, and received her law degree from Osgood Hall Law School. 

Yanick Labrie (M.Sc., B.A.)

Yanick Labrie is a health economist and public policy consultant living in Montreal. He holds a bachelor’s degree in economics from Concordia University and a master’s degree in economics from the Université de Montréal. Mr. Labrie’s career in health policy spans more than fifteen years. He has worked as an economist at the Montreal Economic Institute, the Center for Interuniversity Research and Analysis on Organizations (CIRANO) and was a lecturer at HEC Montréal’s Institute of Applied Economics. He authored or co-authored more than 40 research papers and studies related to healthcare and pharmaceutical policies. Many of his articles have appeared in The Globe and Mail, The National Post, The Ottawa Citizen, The Montreal Gazette, La Presse and Le Devoir, among other newspapers. He is frequently invited to participate in conferences and debates, and to comment on economic affairs in the media. He has recently spoken at international conferences in Canada and abroad on the lessons to be learned from Europe’s health policy reforms. He has been invited to give testimonies at numerous parliamentary commissions and working groups on a wide range of topics and in court cases as an expert witness.

Sarah Lussier-Hoskyn (M.A., B.A.)

Sarah Lussier Hoskyn earned her Master’s degree in Economics at the University of Waterloo and a Bachelor degree in Economics at McGill University. She has 15 years of experience in pharmaceutical policy research in such areas as Canada’s regulatory and reimbursement performance, private drug plan drug costs trends, pricing policy (PMPRB), the value of R&D investments and clinical trials. From 2015 to 2020, Sarah was Director of Research, and Senior Analyst Regulatory Affairs and Market Access, Innovative Medicines Canada. From 2006 to 2015, Sarah was Engagement Manager, Senior Price Regulation Consultant, and Health Economist Consultant at Brogan Inc. (aka. IMS Brogan, IMS Health, Quintiles IMS, and IQVIA). Sarah co-authored 2 papers on pharmaceutical policy topics that were published in the peer-reviewed journal Frontiers in Pharmacology. Sarah's current focus is to help employers figure out their chronic disease burden in their workplace, diagnose the underlying causes, and find innovative evidence-based solutions to complement their existing benefits and wellness plans to improve their workplace health and productivity, and ultimately to reduce costs. This translates into a research interest in policies for health and wellness benefits that reduce the disease burden and resulting health care costs, and improve overall labour productivity and economic competitiveness.

Mark Mullins (Ph.D., M.A., B.A.)

Dr. Mark Mullins has a B.A. from the University of Saskatchewan, an M.A. from the University of Western Ontario and a Ph.D. from the London School of Economics. He also studied for a year in Taiwan and at the University of Hong Kong. From 1990 to 1998, Dr. Mullins was Chief Economist and Head of Fixed Income Research at Midland Walwyn Capital. He then served as President of MSG Hedge Corporation. Dr. Mullins joined the Fraser Institute in 2003 becoming Executive Director until 2009. He has most recently been CEO of Veras Inc., a consulting and advisory firm specializing in finance and economics, and a global macro portfolio manager. He has served as economic and fiscal policy advisor to a number of Canadian political parties at the provincial and federal level. He was a founding member of Ontario’s Task Force on Competitiveness, Productivity and Economic Progress and a former council member with NSERC, the Canadian federal government’s natural sciences and engineering research granting agency.

Grant Perry (H.B.A.)

Grant Perry is the head of GDP Strategies Inc., a public/government affairs, reimbursement and crisis communications consultancy specializing in managing complex issues in the bio-pharmaceutical and health care industries generally.  He holds an Honours Bachelor Degree in Public Administration and more than 25 years’ experience in government, and the innovative pharmaceutical industry, both in Canada and the UK.  Mr. Perry has detailed understanding and experience in government affairs, market access, pricing, crisis communications and intellectual property. In his 25 years of leading in the healthcare industry, Mr. Perry has been at the heart of the evolution of the pharmaceutical intellectual property policy debate in Canada, including numerous WTO challenges.  He has been involved in the evolution of the federal pricing regime since its inception and has a detailed understanding of the ramifications of the proposed Federal regulatory changes and the potential impact on new and marketed products in Canada.  As the health technology assessment paradigm has developed in Canada, Mr. Perry was part of the original industry/government discussions with both CADTH and CDR and subsequently involved in the evolution of both bodies as well as participating in multiple assessments, negotiations and successful recommendations from both CDR and INESSS (Quebec).  With the current COVID-19 pandemic redefining health care and society, Mr. Perry’s role in pandemic preparedness is notable, with his leadership during the H1N1 pandemic and subsequent vaccine initiatives (H1N1 and seasonal). 

Nigel Rawson (Ph.D., M.Sc.)

Nigel Rawson is a pharmacoepidemiologist and pharmaceutical policy researcher based in Saskatoon, Saskatchewan. Educated in the United Kingdom, he holds an M.Sc. in statistics and a Ph.D. in pharmacoepidemiology. Dr. Rawson has performed epidemiologic studies of the use of drugs and their outcomes for over 40 years and published more than 140 book chapters and articles in peer-reviewed journals. He is also the author of the monograph “Drug Safety: Problems, Pitfalls and Solutions in Identifying and Evaluating Risk.” He held academic research positions in the United Kingdom until the end of 1989 and subsequently held professorships at the University of Saskatchewan and Memorial University of Newfoundland in Canada. His research activities focused on population-based studies of the use and safety of drugs using administrative healthcare utilization data and the evaluation of issues impacting access to new medicines. Dr. Rawson has also been a senior researcher in an independent research centre in one of the United States’ largest health insurers, where he collaborated with the Food and Drug Administration on drug safety studies, and GlaxoSmithKline’s only epidemiologist in Canada providing advice and analysis for the company’s medicines and vaccines. Between 2012 and 2020, Dr. Rawson was President of Eastlake Research Group whose mission was to create evidence-based responses to pharmaceutical and health policy issues. He continues this work as an independent researcher. 

Mayvis Rebeira (Ph.D., M.A., M.B.A., B.Sc)

Mayvis Rebeira is a health economist with over fifteen years of experience in government, biotechnology and pharma industries, medical devices and consulting in both Canada and the US. She obtained her Ph.D. in Health Economics from the Dalla Lana School of Public Health at the University of Toronto and holds a Master’s Degree in Economics also from University of Toronto. She has spearheaded economic evaluations of biotech drugs including orphan drugs, strategic drug pricing, market access, health policy development and numerous real-world analysis and cost-effectiveness projects for both the private and the public sectors. Dr. Rebeira has published in the fields of health technology assessments (HTA), economic evaluations and health outcomes.  Her current research interests include developing methodologies for evaluating value-for-money of new drugs and investigating macro-economic conditions on population health.

Walter Robinson (H.B.Com.)

Walter Robinson is an accomplished and bilingual public affairs executive with over 20 years of experience in achieving public policy change at every level of government. He holds an Honours Bachelor of Commerce degree and is a nationally recognized advisor who combines a deep knowledge of parliament and the machinery of government with integrated and compelling advocacy and communications strategies to succeed in complex and politically charged environments. He has served as a national spokesperson conducting thousands of interviews while authoring hundreds of columns/OPEDs and several dozen legislative submissions. Along with driving legislative victories in federal Budgets, he has worked with public officials to secure contracts and funding agreements, and spent time as Chief of Staff to the Mayor Of Ottawa. For the last 15 years he has held Vice President roles with Rx&D (now known as Innovative Medicines Canada), worked as a Senior Director in the pharmaceutical industry. and served in hospital governance and health charity leadership positions.

Mark Rovere (Ph.D. Candidate, M.A., B.A.)

Mark Rovere was a Senior Policy Advisor in the Health System Strategy and Policy Division at the Ontario Ministry of Health and Long-Term Care. Mr. Rovere was Associate Director (2010 to 2012) and Senior Policy Analyst (2006 to 2010) in the health policy research centre at the Fraser Institute. Mr. Rovere holds an Honours Bachelor's degree and a Master's Degree in Political Science from the University of Windsor, and is currently completing a Ph.D. in Health Services Research (health policy) at the University of Toronto's Institute of Health Policy, Management and Evaluation (IHPME). He has authored and co-authored numerous studies and articles on a wide-range of health and pharmaceutical policy related issues including the sustainability of government health expenditures in Canada, wait times for medical services, access to new medicines, Canadian and American prescription drug spending, and international health system comparisons. His commentaries have appeared in newspapers across Canada, and Mr. Rovere has regularly appeared on radio and television programs across the country to discuss his research and health policy issues more generally.

Brett J Skinner (Ph.D., M.A., B.A.)

Brett J Skinner is the Founder and CEO of Canadian Health Policy Institute (CHPI) and the Editor of CHPI's online journal Canadian Health Policy. Dr. Skinner was Executive Director Health and Economic Policy at Innovative Medicines Canada (2013 to 2017); and CEO (2010 to 2012) and Director of Health Policy Studies (2004 to 2012) at Fraser Institute. Dr. Skinner has B.A. and M.A. degrees from the University of Windsor with joint studies at Wayne State University, and a Ph.D. from Western University where he has lectured in both the Faculty of Health Sciences and the Department of Political Science. Dr. Skinner is the principal author or co-author of one book and over 75 major health policy research publications. His work has been published by think-tanks including Canadian Health Policy Institute (Toronto), Fraser Institute (Vancouver), Atlantic Institute for Market Studies (Halifax), Pacific Research Institute (San Francisco), Israel National Institute for Health Policy and Health Services Research (Tel Aviv), Galen Institute (Washington, D.C.), International Policy Network (London) and American Enterprise Institute (Washington, D.C.). His work has also been published in academic journals including Economic Affairs, Pharmacoeconomics,  and Alimentary Pharmacology & Therapeutics. In 2003 he was a co-author on a project that won the Atlas Economic Research Foundation’s Sir Antony Fisher Memorial Award for innovative projects in public policy. Dr. Skinner’s book, Canadian Health Policy Failures: What’s wrong? Who gets hurt? Why nothing changes, was a finalist for Atlas’ 2009 Fisher book prize. He has also authored hundreds of opinion-editorials published in National Post, Financial Post, Globe and Mail, Toronto Sun, Ottawa Citizen, La Presse, Montreal Gazette, Calgary Herald, Vancouver Sun, Chicago Sun Times, and other major daily newspapers. Dr. Skinner appears and is cited frequently as a health policy expert in the media. He has presented his research at conferences and events in Canada, the United States, Israel and South Africa. Dr. Skinner has provided expert testimony about his research in several Canadian legal cases, and he has testified on three occasions before the House of Commons Standing Committee on Health in Ottawa. He has also briefed bi-partisan Congressional policy staff at the U.S. Capitol in Washington, D.C. Dr. Skinner is a passionate advocate for policies that promote the development of, and access to innovative medical treatments. In 2015, he was diagnosed with an atypical form of early onset Parkinson's disease that is non-responsive to existing medications. He has both an academic interest and a personal health stake in government choices affecting future medical innovation.

Laurie Skinner (R.N., B.H.A)

Laurie Skinner is Manager of Canadian Health Policy Institute (CHPI). Laurie has a Bachelor of Health Administration degree from the Ted Rogers School of Management, Health Services Management Program at Ryerson University (Toronto). She is a Registered Nurse (R.N.). with a Diploma in Health Sciences from St. Clair College (Windsor) and has also studied Business Administration and Social Sciences at the University of Windsor. She has worked in clinical nursing in the Maternal/Newborn Unit and Special Care Nursery at Windsor Regional Hospital's Metropolitan Campus and in the Combined Care Unit at Sunnybrook and Women's College Hospital in Toronto. Laurie has also worked as a Project Coordinator with the Ontario Medical Association (OMA), as a Physician Assistant Recruitment Advisor with HealthForceOntario MRA, and as a Nursing Recruitment Coordinator with the Professional Association of Internes and Residents of Ontario (PAIRO) / HFOJobs (HealthForceOntario). Laurie has made various presentations to HR professionals at 16 Ontario hospitals; staff at the Ontario Ministry of Health and Long Term Care; representatives of several health care organizations including the Ontario Hospital Association; and Nursing students at the University of Toronto, University of Western Ontario, York University and Seneca College.

Shahzia Teja (M.A., B. Comm.)

Shahzia Teja is an Economist with the Ontario Ministry of Finance. Ms. Teja’s academic interests include welfare economics and data science, and her work has been published in the journal Canadian Public Policy. She has an M.A. in Economics and a B.Comm. in Finance from the University of Guelph and is a member of the Canadian Economics Association. Ms. Teja is motivated by an interest in the profound and tangible ways in which healthcare policies affect people, and the opportunity that empirical methods and incentives offer in achieving better outcomes, both for providers and patients.

Louis Thériault (M.A., B.A.)

Fluently bilingual, Louis holds an Honours Bachelor of Arts degree and a Master's degree in Economics from Université Laval in Québec City. He worked for 20 years at The Conference Board of Canada, an applied research organization, specializing in the areas of economic trends, industry and business strategy, leadership and human resources, and public policy. Louis led several major Conference Board projects including, the Canadian Alliance for Sustainable Health Care, the International Trade and Investment Centre, and the Canadian Industrial Outlook and Metropolitan Outlook forecasting services. More recently, he was Vice President, Policy and Research at Innovative Medicines Canada, the national association representing research-based pharmaceutical companies. Louis is recognized for succeeding in complex multi-stakeholder environments characterized by ambiguity and competing priorities. His skills as speaker and a media spokesperson on public policy issues and the Canadian economy have been instrumental in communicating key messages for decision-making purpose in these environments.

Subscribe image

CHP blogazine